Related Experiment Video
Updated: May 23, 2026

Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts
Published on: February 23, 2024
Treatment of hyperferritinemia
Melanie D Beaton1, Paul C Adams
1University of Western Ontario, London Health Sciences Centre, Department of Medicine, Division of Gastroenterology, Canada.
Elevated serum ferritin (hyperferritinemia) is common but rarely indicates iron overload. Treatment decisions for hyperferritinemia should be individualized based on specific patient factors.
Area of Science:
- * Clinical Biochemistry
- * Internal Medicine
- * Hematology
Background:
- * Elevated serum ferritin, termed hyperferritinemia, is frequently identified during routine blood tests.
- * This finding often necessitates further medical investigation to determine the underlying cause.
- * Hyperferritinemia is not always indicative of true iron overload conditions.
Purpose of the Study:
- * To review the diverse etiologies of hyperferritinemia.
- * To differentiate hyperferritinemia from true iron overload.
- * To discuss the ongoing debate regarding mechanisms and clinical significance.
Main Methods:
- * Literature review of studies on hyperferritinemia.
- * Analysis of causes and clinical implications.
- * Evaluation of treatment strategies.
Main Results:
- * Hyperferritinemia has numerous causes, most not involving iron overload.
- * The exact mechanisms and disease impact of hyperferritinemia remain under investigation.
- * Evidence for iron reduction benefits is mixed and requires careful consideration.
Conclusions:
- * Hyperferritinemia is common and usually benign, not signifying iron overload.
- * Individualized treatment is crucial, considering patient-specific factors and iron overload markers.
- * Further research is needed to clarify the role and management of hyperferritinemia.
Related Concept Videos
The Early Endosome: Endocytosis of Transferrin
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Chronic Pancreatitis II: Collaborative Care
Assessment:

